Disrupting the Clinical Trial Process with Ramita Tandon
A Conversation with Ramita Tandon
Ramita Tandon, Chief Clinical Trials Officer, Walgreens
Ramita Tandon is the Chief Clinical Trials Officer at Walgreens and responsible for leading and driving growth for the Company’s new clinical trials business. Ramita brings more than 25 years of leadership and operational experience across a portfolio of industry-leading businesses and services in real-world evidence and patient-centered health outcomes in company such as Trio Health and ICON. Ramita is an internationally recognized speaker and author whose focus is on how to bridge the gap between commercial and clinical development.
Listen to the Conversation
- Ramita Tandon, Chief Clinical Trials Officer at Walgreens, joins Gil to discuss how she’s leading and driving growth within this new division of the corporation to help connect patients with effective breakthrough treatments more quickly.
- There’s a need to disrupt the clinical trial process. How can we find patients and deliver better health outcomes? We’ve needed a change for a very long time, and we need to push the envelope and challenge the status quo in the drug development process, whether that’s designing better protocols or engaging patients more effectively, we need to do what we can to move the needle for people who need it.
- The clinical trials ecosystem is vast and fragmented, like the healthcare system broadly. Walgreens evaluated what they can provide that’s different from what’s been done in the past, and ultimately it comes down to reach. 75% of the United States population lives within 5 miles of a Walgreens and by taking learnings from decades of clinical trial challenges, Walgreens can make a real difference.
- Consumerism in healthcare is complicated. A consumer-focused healthcare industry is inevitable, but it’s isolating and exhausting for so many people. Care doesn’t always reach those that need it, and the drug development process is frustratingly slow and produces disparate outcomes that leave people confused or mistrustful. All the players in the healthcare ecosystem must align and optimize the value chain, keeping up with the patient and consumer’s needs. Patients ought to be thought of as a consumer and the drug development system has to take their needs into greater account.
- Leaders across the spectrum are re-focusing on developing a more robust, patient-centric healthcare framework to improve the patient experience to drive better outcomes. To solve the big problems of access coordination, continuity, engagement, and personalization organizations must redefine the patient experience and increase access across communities that have never had access to clinical research before. When communities are educated about the value of clinical trials to their health outcomes, that will break down barriers of participation and retention in clinical trials.
Managing Partner, Chair Global Health, FINN Partners
LinkedIn: Gil Bashe
Founder & Managing Director, Health Innovation Media
LinkedIn: Gregg Masters, MPH
About the Show
Join digital health advocate and author Gil Bashe, on Health Unabashed, as he discusses the power of collaboration and innovation in improving care across the health ecosystem. Sharing stories and insights from a global perspective, Gil looks at the companies and people who are making a difference and offers his opinions on how to connect the dots to transform the industry for good.
On the radio weekdays at 10:30 am, 6:30 pm, & 2:30 am ET.